<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873103</url>
  </required_header>
  <id_info>
    <org_study_id>BSMO 2014-2</org_study_id>
    <nct_id>NCT03873103</nct_id>
  </id_info>
  <brief_title>The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment</brief_title>
  <official_title>The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment - Precision 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Belgian Society of Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Belgian Society of Medical Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRECISION 1 will enroll patients with metastatic solid tumors. The local PI will verify if&#xD;
      the candidate patient fits the inclusion/ exclusion criteria.&#xD;
&#xD;
      The participant will sign the PRECISION 1 informed consent. NGS data will be collected from&#xD;
      local panel testing on DNA extracted from tissue samples or plasma.&#xD;
&#xD;
      Data will be collected from further molecular testing performed at the different&#xD;
      laboratories: select rearrangements (fusion genes and translocations) by RT PCR, FISH or NGS;&#xD;
      copy number variations of selected genes via the NGS platform (if possible) or using FISH or&#xD;
      other technologies such as SNP arrays in case the NGS technology is incapable of giving this&#xD;
      information.&#xD;
&#xD;
      Results will be stored in the Precision Belgium section of the Healthdata database.&#xD;
&#xD;
      Data on germline variants will also be collected in the Healthdata database whenever this&#xD;
      information is available.&#xD;
&#xD;
      The cooperating clinical investigator will decide with the patient the treatment strategy,&#xD;
      -guided by the best interest of the patient and the availability of respective options :&#xD;
&#xD;
        -  &quot; Empirical &quot; available approved treatment (for example chemotherapy, immunotherapy)&#xD;
&#xD;
        -  Genotype-driven standard of care&#xD;
&#xD;
        -  Inclusion in a genotype-matched clinical trial (includes signing of trial-specific IC)&#xD;
&#xD;
        -  Inclusion in PRECISION 2 if options 2/3 not available. Irrespective of treatment choice,&#xD;
           the patient will be followed by the collaborating clinician and will have follow-up data&#xD;
           collected every 6 months for determination of disease status and survival endpoints.&#xD;
&#xD;
      Clinical data will be collected and stored in the Healthdata database. Genomic data (somatic&#xD;
      and germline whenever available) and clinical data (tumor type and stage, number of previous&#xD;
      lines, treatment choice, response rate, PFS on chosen and previous treatments, …) will be&#xD;
      uploaded on the Healthdata platform and can be consulted via password-protected web access by&#xD;
      the local PI at each participating center. European regulation protecting patient privacy&#xD;
      will apply (&quot;GDPR&quot;).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of patients with &quot;actionable&quot; driven mutations.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients enrolled in genomics-driven clinical trials and in the PRECISION 2 clinical trial.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical benefit rate as defined by survival and/or objective response rate and rate of stable disease lasting more than 6 months with genomics-driven therapy in non-approved indications</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Metastatic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        1000 patients with metastatic solid tumors that are eligible for systemic therapy will be&#xD;
        recruited at 7 Belgian academic centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic solid tumors that are candidates for systemic therapy (early&#xD;
             lines are preferred).&#xD;
&#xD;
          -  Patient showing an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤&#xD;
             2.&#xD;
&#xD;
          -  Patients able to provide written informed consent prior to enrollment into a&#xD;
             subsequent clinical trial.&#xD;
&#xD;
          -  Patients agrees to provide NGS data (somatic and/or germline) as well as clinical data&#xD;
             baseline and during follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of less than 12 weeks.&#xD;
&#xD;
          -  Inability to comply with protocol procedures.&#xD;
&#xD;
          -  Known presence of severe hematopoietic, renal, and/or hepatic dysfunction (according&#xD;
             to the local PI).&#xD;
&#xD;
          -  Targeted gene sequencing on DNA extracted from decalcified bone biopsies is not&#xD;
             accepted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Aftimos, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Jules Bordet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gordana Raicevic Toungouz, PhD</last_name>
    <phone>003226425490</phone>
    <email>gordana.raicevictoungouz@sciensano.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk Schrijvers, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerp</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luc Dirix, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charis Loos</last_name>
    </contact>
    <investigator>
      <last_name>Wim Demey, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Kim Bergström</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Aftimos, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Cappoen</last_name>
    </contact>
    <investigator>
      <last_name>Lore Decoster, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Les Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Papier</last_name>
    </contact>
    <investigator>
      <last_name>François Duhoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marika Rasschaert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lore Vansteelant</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie Rottey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Schroeder</last_name>
      <email>hschroeder@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Joelle Collignon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Willem Lybaert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

